RUNX Proteins as Epigenetic Modulators in Cancer

Hongyang Yi\textsuperscript{1,2,3,†}, Yuhao He\textsuperscript{1,2,†}, Qionghua Zhu\textsuperscript{1,2} and Liang Fang\textsuperscript{1,2,4,*}

\textsuperscript{1} Shenzhen Key Laboratory of Gene Regulation and Systems Biology, School of Life Sciences, Southern University of Science and Technology, Shenzhen 518055, China
\textsuperscript{2} Department of Biology, School of Life Sciences, Southern University of Science and Technology, Shenzhen 518055, China
\textsuperscript{3} National Clinical Research Centre for Infectious Diseases, The Third People’s Hospital of Shenzhen and The Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen 518112, China
\textsuperscript{4} Academy for Advanced Interdisciplinary Studies, Southern University of Science and Technology, Shenzhen 518055, China

* Correspondence: fangl@sustech.edu.cn; Tel.: +86-138-2328-8350

† These authors contributed equally to this work.

Abstract: RUNX proteins are highly conserved in metazoans and perform critical functions during development. Dysregulation of RUNX proteins through various molecular mechanisms facilitates the development and progression of various cancers, where different RUNX proteins show tumor type-specific functions and regulate different aspects of tumorigenesis by cross-talking with different signaling pathways such as Wnt, TGF-\(\beta\), and Hippo. Molecularly, they could serve as transcription factors (TFs) to activate their direct target genes or interact with many other TFs to modulate chromatin architecture globally. Here, we review the current knowledge on the functions and regulations of RUNX proteins in different cancer types and highlight their potential role as epigenetic modulators in cancer.

Keywords: RUNX family; cancer; function; regulation; epigenetic modulator

1. Introduction

The RUNX TFs, which include RUNX1, RUNX2, and RUNX3, are master regulators of diverse developmental processes such as neurogenesis, hematopoiesis, and osteogenesis [1–3]. Over the past few decades, there has been a great advance in understanding the function of the RUNX family in cancer, suggesting its members as promising targets for cancer diagnosis and therapy [1,2,4–7]. Each member of the RUNX family is directly involved in multiple stages of tumorigenesis, such as the tumor formation, proliferation, apoptosis, and metastasis [1,8–19]. RUNX1 inactivation promotes the occurrence of hematological malignancies and plays a pivotal role in skin [13], breast [20,21], liver [22], and colorectal cancers [23,24]. The direct involvement of RUNX2 in tumorigenesis has been rarely reported, while the function of RUNX2 in regulating epithelial to mesenchymal transition (EMT) [19,25] and drug resistance [26] in cancer has been recently reported. RUNX3 exerts a dual function in cancer. On the one hand, it functions as a tumor suppressor in liver [27,28], lung [29–32], breast [33,34], and pancreatic cancer [9,26,35]; on the other hand, its expression level is negatively correlated with survival in head and neck squamous cell carcinomas (HNSCC) [12,36]. RUNX proteins not only activate their direct target genes, but also interact with many other TFs involved in various signaling pathways to modulate the development and progression of cancer [24,37–39], such as the ability of RUNX3 to directly interact and suppress the activity of the \(\beta\)-catenin/TCF4 complex [40,41]. In addition to acting as critical TFs, recent studies have revealed that RUNX proteins could act as pioneer factors in cancer. Our recent study showed that RUNX2 could act as a pioneer factor to modulate the epigenetic landscape to promote the EMT program [19]. This review...
summarizes the current knowledge on the functions and regulations of RUNX proteins in different cancer types and highlights their role as potential epigenetic modulators in cancer.

2. The RUNX Family Proteins

In mammals, the RUNX family consists of RUNX1, RUNX2, and RUNX3, each with two alternative promoters: a distal P1 promoter and a proximal P2 promoter (Figure 1A) [2,3,42]. These transcripts encode RUNX proteins with different N-terminal sequences. The distal isoform typically starts with the Met-Ala-Ser-(Asp/Asn)-Ser motif and the proximal isoform starts with the Met-Arg-Ile-Pro-Val amino acid sequence [42]. The diversity of RUNX transcripts was further increased by alternative splicing. In general, RUNX1 has 9 exons and 12 isoforms, and RUNX2 has 9 exons and 12 isoforms, while RUNX3 has only 7 exons and 2 isoforms [2,3,43–45].

![Figure 1. Structures of RUNX1, RUNX2, and RUNX3 genes and proteins. (A) Genetic structures of RUNXs. P1 (distal) and P2 (proximal) promoters are shown. Both Runt homology domain (RHD, red) and transactivation domain (TADs, blue) are present in RUNX proteins. Start codons are indicated by down arrows; coding sequences are shown in orange, red, and blue; and untranslated regions (UTRs) are in gray. (B) Protein structures of RUNXs. The amino acid sequences of Runt homology domain (RHD, red) are highly conserved among RUNX proteins. Other common domains include the nuclear localization signal (NLS, light purple), the transactivation domain (TAD, dark blue), the inhibitory domain (ID, light cyan), and the C-terminal Groucho/TLE binding site (VWRPY, green). The glutamine/alanine-rich (QA, light blue) sequence is RUNX2-specific.](image-url)

There is a highly conserved Runt homology domain (RHD) near the N-terminus of RUNX proteins, which contains 128 amino acids and mediates the binding of RUNX proteins to the DNA at the consensus RUNX motif ‘PyGPyGGTPy’ (Figure 1B) [3,42]. Meanwhile, RHD can mediate protein–protein interactions and nuclear localization of RUNX proteins. The C-terminus of the RUNX proteins is less conserved compared to the N-terminus and includes mainly the transactivation domains (TAD), the inhibitory domain (ID), and the VWRPY repression motif. VWRPY is a highly conserved motif which recruits the Groucho/Transducin-like enhancer protein (TLE) family co-repressor [3,46]. The genomic architecture and protein structures of the RUNX family TFs are shown in Figure 1.

3. Biological Functions of RUNX Proteins in Development

RUNX1 is a key regulator of hematopoietic cell development [3,47,48]. During mouse embryonic development, RUNX1 is essential for the generation of hematopoietic stem cells, and the deletion of Runx1 blocks the hematopoiesis process. It shows similar functions in zebrafish [49–51]. Meanwhile, recent studies have shown that RUNX1 also plays an important role in neuron development [46]. RUNX2 regulates bone formation and development.
mainly by regulating the expression of RANKL, OPG, and other genes [46,52,53]. Knockout of Runx2 in mice inhibits osteoblast differentiation, leading to the occurrence of osteoporosis [54]. Loss of function of RUNX2 also leads to the development of cranioclavicular hypoplasia syndrome, which is associated with impaired clavicular regeneration, abnormal tooth development, and delayed closure of cranial suture [55,56]. RUNX3 is an essential gene in embryonic development, whose knockout leads to early postnatal death [8,57]. In addition, studies have shown that RUNX3 is closely associated with the development of the nervous system, bone, and immune cells [2,42,46,58].

4. Contributions of RUNX Proteins to Carcinogenesis

4.1. The Intricacy Function of RUNX1 in Tumorigenesis

RUNX1 plays an important role in the development of the hematopoietic system and its mutations lead to the occurrence of hematological malignancies, such as acute myeloid leukemia (AML), acute lymphoid leukemia (ALL), and familial platelet disorder with a predisposition to acute myeloid leukemia (FPD/AML) [2,47,48,59–61]. Given that the majority of RUNX1 mutations detected in these patients are defined as loss-of-function mutations, RUNX1 is considered to function primarily as a tumor suppressor in these cancers. However, many studies have revealed that RUNX1 has cancer-promoting properties in solid tumors (Table 1). In many solid tumors, including colon, ovarian, and breast cancers, the expression level of RUNX1 is significantly increased compared to paracancerous tissue [7,22–24,62–64]. In a mouse model of skin cancer, deletion of Runx1 reduced the number of chemo-induced tumors [13,65]. In colorectal cancer, overexpression of RUNX1 promotes the ability of cells to migrate both in vivo and in vitro through activating the Wnt signaling pathway [23,24]. Poor survival in ovarian cancer patients is correlated with high RUNX1 expression levels, and depletion of RUNX1 in ovarian cancer cells elevates cisplatin sensitivity [16,66,67]. In addition, in HNSCC, reduced RUNX1 expression suppresses the ability of cells to migrate and proliferate in vitro and reduces tumor size in vivo [6,63]. In glioblastoma, inhibition of RUNX1 expression significantly abrogated the migratory and invasive ability of U-87 MG cells [62].

Table 1. Functions of RUNX family proteins in cancer.

| Gene      | Cancer Type                        | Function                                      | Oncogene (OG) or Tumor Suppressor Gene (TSG) | Refs |
|-----------|------------------------------------|-----------------------------------------------|---------------------------------------------|------|
| **RUNX1** | Skin cancer                        | promotes tumor formation                      | OG                                          | [13,65] |
|           | Colorectal cancer                  | promotes cell migration                       | OG                                          | [23,24] |
|           | Ovarian cancer                     | elevates drug resistance                      | OG                                          | [15,66,67] |
|           | HNSCC                              | promotes cell migration and proliferation     | OG                                          | [6,63] |
|           | Glioblastoma                       | promotes cell migration and invasion          | OG                                          | [62] |
|           | Breast cancer                      | promotes cell metastasis                      | OG                                          | [68] |
|           | Hepatocellular carcinoma           | inhibits carcinogenesis                       | TSG                                         | [20] |
|           |                                    |                                               |                                             |      |
| **RUNX2** | Osteosarcoma                       | promotes tumor formation and metastasis       | OG                                          | [1,14,69–72] |
|           | Thyroid carcinoma                  | promotes EMT and angiogenesis                 | OG                                          | [25] |
|           | Lung cancer                        | promotes cell migration and proliferation     | OG                                          | [70] |
|           | Breast, colon, bladder, glioma, cervical, and liver cancer | promotes cell migration | OG                                          | [15,19] |
|           | Pancreatic cancer                  | elevates drug resistant                       | OG                                          | [26] |
| **RUNX3** | Lung cancer                        | inhibits carcinogenesis                       | TSG                                         | [29,30,57] |
|           | Gastric cancer                     | inhibits cell proliferation and metastasis   | TSG                                         | [1–3,71] |
|           |                                   | inhibits cell proliferation                   | TSG                                         | [9] |
|           | HNSCC                              | negatively correlated with survival in clinical | OG                                          | [12,36] |
|           | Colorectal cancer                  | promotes apoptosis and inhibits metastasis    | TSG                                         | [11,72] |
|           | Breast cancer                      | inhibits cell proliferation and metastasis   | TSG                                         | [73] |
|           | Pancreatic cancer                  | promotes cell metastasis                      | OG                                          | [74] |
Interestingly, RUNX1 could act both as an oncogene and a tumor suppressor in breast cancer [20,21,64,65,75–77]. On the one hand, RUNX1 could promote breast cancer metastasis in vivo, where the expression of RUNX1 rises during the metastasis of tumor cells from the primary site to the distal lung [68]. Moreover, inhibiting the expression of RUNX1 significantly reduced the invasive and migratory capacity of the cells [68]. On the other hand, it was demonstrated that the depletion of RUNX1 could promote the estrogen-induced Wnt signaling pathway in luminal breast cancer cells by suppressing AXIN1 [23]. Van Bragt et al. found that the loss function of RUNX1 in the context of loss function of RB1 or TP53 may promote luminal breast carcinogenesis [20]. The tumor suppressive function of RUNX1 was also observed in hepatocellular carcinoma, where increased expression of RUNX1 could suppress cell migration and proliferation [22].

4.2. RUNX2 Promotes Cancer Metastasis

The major function of RUNX2 in the context of cancer is to promote cancer metastasis. In the skeleton system, RUNX2 is not only involved in the development, but also plays a crucial role in the formation and metastasis of osteosarcoma [1,14,78]. Lau et al. found that the chromosomal region of RUNX2 6p12-p21 was amplified in osteosarcoma, which was associated with the increased metastatic and tumorigenic properties and decreased survival rate [69,79,80]. In thyroid carcinoma, abolishing the expression of RUNX2 suppresses the expression of EMT and angiogenesis-related factors [25]. Breast cancer cells with higher RUNX2 expression have a stronger ability to migrate, partly due to the upregulation of EMT-related genes such as MMP2, MMP9, MMP13, BSP, etc. [15]. Meanwhile, in Vishal’s study, RUNX2 was found to promote breast cancer metastasis to bone [81]. Depletion of RUNX2 improves BMP-3b transcription by decreasing the methylation level of the BMP-3b promoter, thereby inhibiting migration and proliferation of lung cancer cell line H1299 [70]. Recently, our study showed that cells with activated Wnt signaling and EMT program showed higher RUNX2 expression in a heterogeneous colorectal cancer cell population and that overexpression of RUNX2 enhanced cell migration in colon cancer cells, as well as in many other cancer cells, including bladder, glioma, cervical, liver, and lung cancers [19]. We further revealed that RUNX2 could act as a pioneer factor to reshape the chromatin landscape globally to promote an EMT program.

RUNX2 has also been found to facilitate other aspects of tumorigenesis. In prostate cancer cells, RUNX2 activates the transcription of Survivin by binding to the Survivin promoter and subsequently inhibits cell apoptosis and enhances cell survival in vitro [82–84]. Ozaki et al. found that RUNX2 increased resistance to gemcitabine in pancreatic cancer cells [26].

4.3. Dual Roles of RUNX3 in Tumorigenesis

RUNX3 has been reported as a tumor suppressor in an increasing number of studies [8,9,33,85–92]. Loss of the chromosomal region (1p36), where RUNX3 is located, is frequently found in various cancers, such as breast, liver, lung, bowel, nerve, and pancreatic cancers [93]. Most remarkably, 20–40% of neuroblastoma cases show loss of heterozygosity at 1p36 [89]. Lee’s work has shown that Runx3+− mice spontaneously acquired lung adenomas around 18 months of age, whereas Runx3−− mice died from lung epithelial hyperplasia soon after birth [29,57]. Specific knockout of Runx3 in the lungs of adult mice resulted in dysregulated differentiation of lung epithelial cells and development of lung adenocarcinoma [30,57]. In different cancer types, such as lung, bone, bladder, and colon, RUNX3 expression was found to be suppressed by hypermethylation of the promoter region [33,73,89,94,95]. For example, Helicobacter pylori infection, a primary cause of gastric cancer, could lead to promoter hypermethylation of many tumor suppressor genes, including RUNX3 [1–3]. Increasing RUNX3 expression by demethylating its promoter could restrict the cell proliferation in gastric cancer [1–3]. The identification of the tumorigenic mutation R122C of RUNX3 in gastric and head and neck cancers was a significant breakthrough in understanding the mechanism how RUNX3 inhibits carcinogenesis [8]. The
R122C mutation was shown to completely abrogate the function of RUNX3 as a tumor suppressor; while overexpression of RUNX3 slowed the proliferation of different cancer cells, overexpression of the R122C mutant failed to inhibit cell proliferation. Mislocalization of the RUNX3 protein in the cytoplasm also affects its tumor suppressor function, as has been reported in colorectal, breast, and gastric cancers [3,8,33,89].

In addition to its tumor suppressor function, RUNX3 can promote tumor development under special circumstances. Whittle et al. found that RUNX3 could also act as an oncogene and promote cell metastasis in pancreatic ductal adenocarcinoma [74]. Moreover, RUNX3 expression is higher in HNSCC than in normal tissues and is negatively correlated with survival in clinical settings [12,36].

5. The Regulation of RUNX Proteins in Cancer

5.1. At the Genetic Level

Somatic mutations in RUNX2 and RUNX3 are rare in different cancers. However, mutations of RUNX1 are detected in hematological malignancies frequently and less frequently in some solid tumors. In clinical studies, ~10% of AML patients were identified to have translocations near the RUNX1 chromosomal region [96,97], ~7% of esophageal cancer patients had RUNX1 deletion mutations [98], and ~4% of breast cancer patients had RUNX1 inactivating mutations (Table 2) [17]. In some hematological malignancies, RUNX1 proteins have been found to fuse with other genes, such as RUNX1-ETO fusion in 10–20% of AML patients and TEL-RUNX1 fusion in 20–25% of childhood ALL patients [65,99].

Table 2. Dysregulation of RUNX family proteins at different levels in cancer.

| Gene       | Level of Regulation | Type of Regulation   | Cancer Type                        | Refs       |
|------------|---------------------|----------------------|-----------------------------------|------------|
| RUNX1      | Genetic level       | Translocation        | AML                               | [96,97]    |
|            |                     | Deletion mutation    | Esophageal cancer                 | [98]       |
|            |                     | Inactivating mutation | Breast cancer                     | [17]       |
|            |                     | Gene fusion          | Hematological malignancies        | [65,99]    |
|            | Transcriptional     | Wnt signaling        | Leukemia                          | [100]      |
|            |                     | Hypoxia signaling    |                                    | [101]      |
|            | Post-transcriptional| LncRNA-uc002yug.2    | Esophageal squamous cell carcinoma | [102]      |
|            |                     | Acetylation          | Leukemia                          | [103]      |
| RUNX2      | Transcriptional     | BRD4, c-JUN, ATF3, and HDACs | Thyroid and breast cancers       | [104,105] |
|            |                     | Wnt signaling        | Colorectal cancer                 | [19]       |
|            | Post-transcriptional| miR-34c              | Osteosarcoma                       | [106]      |
|            |                     | miR-135 and miR-203  | Breast cancer                      | [107]      |
|            | Post-translational  | Phosphorylation      | T-cell lymphoma                    | [108]      |
| RUNX3      | Genetic             | Deletion mutations   | Breast, liver, lung, bowel, nerve, and pancreatic cancers | [93]       |
|            |                     | Loss of heterozygosity | Neuroblastoma                     | [93]       |
|            |                     | Hypermethylation     | Lung, bone, bladder, colon, and gastric cancers | [1–3,33,73,89,94,95] |
|            | Transcriptional     | Notch signaling      | Endothelial cells                 | [109]      |
|            | Post-translational  | Phosphorylation      | Breast cancer                      | [110]      |
|            |                     | Ubiquitination       |                                    | [111]      |
|            |                     | Mislocalization      | Breast and gastric cancers         | [8,112]    |

5.2. At the Transcriptional Level

The expression of RUNX can be regulated at the transcriptional level by diverse molecular mechanisms in cancer (Figure 2). In thyroid and breast cancers, RUNX2 transcription requires three distantly located enhancers (ENHs) in a chromatin three-dimensional looping. BRD4 could bind to ENHs and control RUNX2 expression, while c-JUN is pivotal for the interaction of ENHs with a set of TFs [104]. In bone metastatic breast cancer, Gokulnath et al. found that the RUNX2 promoter can be bound and activated by ATF3 [105]. In a variety of cancer cell lines, epigenetic regulators HDAC1 and other HDAC proteins could
bind to the RUNX2 P2 promoter to potentiate its transcription. In thyroid cancer cells, HDAC6 could stabilize the transcriptional complex of RUNX2 [113].

**Figure 2.** Overview of the regulation of RUNX proteins in cancer. RUNX proteins are regulated through different molecular mechanisms at different levels of gene regulation. Cyan, RUNX family proteins; red, RUNX family mRNA; purple, RUNX family gene locus; green, enzymes that induce increased levels of RUNX family proteins; pink, enzymes that induce a decrease in RUNX family protein levels; blue, ncRNAs.

RUNX proteins are also transcriptional targets of certain signaling pathways, such as Notch and Wnt/β-catenin. While RUNX1 was found to be a downstream target of the Notch signaling pathway in mouse embryonic fibroblasts and mesodermal and hematopoietic stem cells [114–116], RUNX3 was found to be a Notch target in endothelial cells [109]. In leukemia cell lines HL60 and Jurkat, and CD34+ progenitor cells, induction of the Wnt/β-catenin signal increases the expression of the RUNX1 P1 isoform, which may be critical for leukemia onset and progression [100]; in colon cancer cells, RUNX2 was found to be upregulated by the same pathway [19]. Hypoxia signaling is also involved in the regulation of the RUNX protein, with HIF1α and RUNX1 forming a feedback loop that fine-tunes the levels of RUNX1. In this mechanism, HIF1α transcriptionally activates RUNX1, and excess RUNX1 interacts with HIF1α and inhibits its DNA-binding and transcriptional activity [101].

### 5.3. At the Post-Transcriptional Level

RUNX can be regulated by non-coding RNAs, such as miRNA and long non-coding RNA (lncRNA). Huang et al. found that miR-204 and miR-211 could reduce RUNX2’s expression level by binding to the 3’UTR region during adipocyte differentiation [117]. It
is also shown that miR-34c expression induced by P53 could reduce the expression level of RUNX2 and impair the metastatic ability of osteosarcoma cells [106]. The miR-135 and miR-203 were found to inhibit the malignant phenotypes of breast cancer cells by repressing RUNX2 [107].

LncRNA-CASC2 could antagonize miR-18a-5p-mediated repression of RUNX1, leading to reduced proliferation of multiple myeloma cells [118]. LncRNA-MALAT1 has been shown to promote colorectal cancer metastasis by interacting with RUNX2 at different steps of transcription and translation. MALAT1 could bind miR-15 to antagonize its repression on LRP6, resulting in elevated transcript levels of RUNX2 [119]. In addition, MALAT1 could bind to splicing factor SFPQ and interact with the IRES domain in the 5′UTR of RUNX2 mRNAs to elevate RUNX2 protein level [119]. LncRNA-uc002yug.2 can promote the binding of RUNX1 to an alternative splicing factor, leading to the production of more RUNX1a, thus promoting the progression of esophageal squamous cell carcinoma (ESCC) [102].

5.4. At the Post-Translational Level

RUNX proteins can be differentially regulated at the post-translational level, thereby affecting RUNX proteins in many aspects, such as stability, activity, and subcellular localization. For example, P300 acetyltransferase acetylates the lysine residues of RUNX1 and RUNX3. In leukemic cells, this modification was shown to increase the DNA binding ability of RUNX1 and was required for RUNX1-ETO leukemogenicity [103]. In addition, ERK1 and ERK2 phosphorylate RUNX1 in response to cytokine stimulation, thereby enhancing the interaction of RUNX1 with P300 [120,121]. The protein level of RUNX is also regulated by proteasome-mediated degradation [122]. The E3 ubiquitin–protein ligases SMURF1 and SMURF2 were found to promote RUNX degradation, while P300 acetyltransferase was shown to inhibit the degradation of RUNX3. Pim-1 could phosphorylate all RUNX proteins [123], and the phosphorylation mediated by Pim-1 would increase RUNX3’s stability and cytoplasmic location [110]. Upregulation of RUNX2 and Pim-1 was found to synergistically promote the development of T-cell lymphoma, suggesting the phosphorylation mediated by Pim-1 has a positive effect on RUNX2’s cancer-promoting function [108]. In breast cancer, the prolyl isomerase Pin1 recognizes the four phosphorylated Ser/Thr-Pro motifs in RUNX3 through its WW structural domain, thereby cis-trans-isomerizing the proline amino-terminal bond and downregulating the transcriptional activity of RUNX3. In addition, Pin1 induces ubiquitination and proteasomal degradation of RUNX3, reducing the protein level of RUNX3 in an isozyme activity-dependent manner [111].

6. RUNX Proteins Function as Master Regulators of Transcription

Here, we focus on discussing RUNXs’ functions as transcriptional co-regulators of different oncogenic signaling pathways and as pioneer factors capable of modulating chromatin architecture globally, aiming to highlight the role of RUNX proteins as master regulators of transcription.

6.1. Interaction with the Wnt/β-Catenin Signaling Pathway

Hyperactivation of the canonical Wnt signaling pathway contributes to the development and progression of various cancers [124,125]. RUNXs have a complex regulatory relationship with the Wnt signaling [19,37,41]. In hematopoietic progenitor cells and colorectal cancer cells, RUNX1 transcription is regulated by the Wnt signaling [23,100], and LEF1, a co-transcription factor of β-catenin, could interact with RUNX1 and enhance its DNA-binding ability [126]. Study has also shown that RUNX1 could directly interact with β-catenin to enhance the activity of the Wnt signaling pathway in colorectal cancer, thereby enhancing cell migration [21]. Both RUNX2 and the Wnt signaling play essential roles in osteogenesis, a highly dynamic process in which RUNX2 expression is tightly regulated by the Wnt signaling pathway. This regulatory relationship was also observed in colon cancer cells, where RUNX2 works downstream of Wnt signaling to facilitate the EMT pro-
cess [19]. RUNX3 as a tumor suppressor could directly interact with the β-catenin/TCF4 complex, blocking the binding of the complex to DNA and suppressing its transcriptional activity [40,41]. This function is lost in the RUNX3 R122C mutant, which cannot interact with the β-catenin/TCF4 complex [1].

6.2. Interaction with the TGF-β Signaling Pathway

TGF-β signaling regulates a variety of developmental processes, and it produces conflicting phenotypes both in normal tissues and cancer. For instance, it can promote cell proliferation or apoptosis, depending on cellular context [127]. RUNX proteins are important regulators of the TGF-β signaling pathway because they can interact directly with the SMAD proteins, the TFs of TGF-β signaling, to affect the transcription of TGF-β target genes [24,74,128,129]. For instance, the interaction of RUNX3 with SMADs can induce the expression of the p21 protein and thus inhibit the cell cycle progression [10]. In hepatoma cells, RUNX1 can interact with FOXO3A to induce the transcription of BIM, a target gene of the TGF-β signaling pathway [130]. These studies demonstrated how RUNX1 and RUNX3 facilitate the tumor suppressive function of the TGF-β signaling pathway.

6.3. Interaction with the Hippo Signaling Pathway

Recent studies suggest that the Hippo signaling pathway contributes to carcinogenesis by directly regulating its target genes through its nuclear effectors TEAD and YAP/TAZ [38,39,131,132]. RUNX proteins could interact with different nuclear effectors of the Hippo pathway. RUNX3 can abolish TEAD binding to DNA by interacting with the N-terminal region of TEAD through its Runt domain, and this interaction can be impaired by RUNX3 R122C mutation [133]. Interestingly, although the Runt domains of RUNX1/2/3 are highly conserved, the interaction between RUNX2 and TEAD is very weak [38]. In contrast, RUNX2 strongly interacts with YAP/TAZ [134]. In breast cancer, RUNX2 promotes the nuclear localization of TAZ, but not YAP, and therefore enhances the expression of target genes [38,134]. In gastric cancer, the interaction between RUNX3 and TEAD inhibits the transcription of downstream genes, such as CTGF and CY61 [8,10,135,136].

6.4. RUNX Proteins Function as Pioneer Factors

Pioneer factors are defined as TFs that can directly bind the condensed chromatin and recruit other TFs and/or histone modification enzymes to activate transcription [137]. Our recent study demonstrated that by overexpressing RUNX2 alone in a cell population with low Wnt signaling activity and epithelial phenotype, RUNX2 could drive chromatin opening at most of its target loci and subsequently induce the EMT program [19]. Moreover, RUNX3 was found to bind to its target loci, where it opens chromatin structure by sequential recruitment of Trithorax group proteins and cell cycle regulators to drive cells into the restriction point, which is disrupted in nearly all tumors [138]. These studies revealed how RUNX proteins act as pioneer factors, functioning as tumor promoters and suppressors, respectively. Whether RUNX1 has a similar function in specific context remains elusive.

7. Conclusions

As cancer incidence and mortality rates increase, its burden on society is rapidly growing worldwide, underscoring the significance of research aimed at identifying new diagnostic and therapeutic targets. An ever-increasing number of studies have revealed the diverse functions of RUNX proteins in the formation and metastasis of various cancers, highlighting their potential as diagnostic markers or therapeutic targets [1,139–142]. Given that RUNX1 causes hematological malignancies mainly through somatic mutations and functions as a tumor suppressor, RUNX1 is more promising as a target for the treatment of solid tumors, where it is a tumor-promoting gene, with the exception of breast and liver cancers. As for RUNX2, based on its general metastasis-enhancing functions, it could be a promising target for preventing tumor metastasis and predicting patient outcomes. Given
that RUNX3 is more commonly recognized as a tumor suppressor gene, it is more suitable to be developed as a diagnostic marker for solid cancers.

RUNX proteins function as epigenetic regulators in three ways: 1. They regulate the expression of their direct target genes; 2. They interact with TFs downstream of diverse signaling pathways to affect the expression of their target genes; 3. They function as pioneer factors that remodel the chromatin landscape. Given that the pioneer factor function of RUNX proteins has only recently been revealed, further studies are still required to elucidate the context specificity and detailed mechanisms of this function for different RUNX proteins, which is critical for us to understand their contributions to the physiological and pathological conditions. For instance, it would be interesting to identify in which other processes the pioneer factor function of RUNX proteins could be observed, and how RUNXs exert this function through interactions with other TFs or epigenetic modulators. Moreover, for therapeutic development, it would be of interest to test whether the pioneer factor function of RUNXs offers new possibilities for targeting specific features of cancer.

Author Contributions: Conceptualization, L.F. and H.Y.; writing—original draft preparation, H.Y. and Y.H.; writing—review and editing, L.F. and Q.Z.; funding acquisition, L.F. All authors have read and agreed to the published version of the manuscript.

Funding: This work was funded by Shenzhen Key Laboratory of Gene Regulation and Systems Biology (Grant No. ZDSYS2020811144002008), Shenzhen Science and Technology Program (Grant No. KQTD2018041114343237 and JCYJ20190809154407564).

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Chuang, L.S.; Ito, K.; Ito, Y. Roles of RUNX in Solid Tumors. *Adv. Exp. Med. Biol.* 2017, 962, 299–320. [CrossRef] [PubMed]

2. Ito, Y.; Bae, S.C.; Chuang, L.S. The RUNX family: Developmental regulators in cancer. *Nat. Rev. Cancer* 2015, 15, 81–95. [CrossRef] [PubMed]

3. Otalora-Otalora, B.A.; Henriquez, B.; Lopez-Kleine, L.; Rojas, A. RUNX family: Oncogenes or tumor suppressors (Review). *Oncol. Rep.* 2019, 42, 3–19. [CrossRef] [PubMed]

4. Heinze, K.; Rengsberger, M.; Gajda, M.; Jansen, L.; Osmers, L.; Oliveira-Ferrer, L.; Schmalfeldt, B.; Durst, M.; Hafner, N.; Runnebaum, I.B. CAMK2N1/RUNX3 methylation is an independent prognostic biomarker for progression-free and overall survival of platinum-sensitive epithelial ovarian cancer patients. *Clin. Epigenet.* 2021, 13, 15. [CrossRef] [PubMed]

5. Bai, J.; Yong, H.M.; Chen, F.F.; Song, W.B.; Li, C.; Liu, H.; Zheng, J.N. RUNX3 is a prognostic marker and potential therapeutic target in human breast cancer. *J. Cancer Res. Clin. Oncol.* 2013, 139, 1813–1823. [CrossRef]

6. Feng, X.; Zheng, Z.; Wang, Y.; Song, G.; Wang, L.; Zhang, Z.; Zhao, J.; Wang, Q.; Lu, L. Elevated RUNX1 is a prognostic biomarker for human head and neck squamous cell carcinoma. *Exp. Biol. Med.* 2021, 246, 536–546. [CrossRef]

7. Hong, D.; Fritz, A.J.; Gordon, J.A.; Tye, C.E.; Boyd, J.R.; Tracy, K.M.; Frietze, S.E.; Carr, F.E.; Nickerson, J.A.; Van Wijnen, A.J.; et al. RUNX1-dependent mechanisms in biological control and dysregulation in cancer. *J. Cell. Physiol.* 2019, 234, 8597–8609. [CrossRef] [PubMed]

8. Li, Q.L.; Ito, K.; Sakakura, C.; Fukamachi, H.; Inoue, K.; Chi, X.Z.; Lee, K.Y.; Nomura, S.; Lee, C.W.; Han, S.B.; et al. Causal relationship between the loss of RUNX3 expression and gastric cancer. *Cell 2002*, 108, 113–124. [CrossRef]

9. Wada, M.; Yazumi, S.; Takaishi, S.; Hasegawa, K.; Sawada, M.; Tanaka, H.; Ida, H.; Sakakura, C.; Ito, K.; Ito, Y.; et al. Frequency of RUNX3 gene expression in human bile duct and pancreatic cancer cell lines. *Oncogene* 2004, 23, 2401–2407. [CrossRef] [PubMed]

10. Hoi, C.S.; Lee, S.E.; Lu, S.Y.; McDermitt, D.J.; Osorio, K.M.; Piskun, C.M.; Peters, R.M.; Paus, R.; Timbar, T. Runx1 directly promotes proliferation of hair follicle stem cells and epithelial tumor formation in mouse skin. *Mol. Cell. Biol.* 2010, 30, 2518–2536. [CrossRef] [PubMed]

11. Liu, Q.L.; Ito, K.; Sakakura, C.; Fukamachi, H.; Inoue, K.; Nomura, S.; Lee, C.W.; Han, S.B.; et al. Causal relationship between the loss of RUNX3 expression and gastric cancer. *Cell 2002*, 108, 113–124. [CrossRef]

12. Tsumematsu, T.; Kudo, Y.; Iizuka, S.; Ogawa, I.; Fujita, T.; Kurilchik, H.; Abiko, Y.; Takata, T. RUNX3 has an oncogenic role in head and neck cancer. *PLoS ONE 2009*, 4, e5892. [CrossRef]

13. Hoi, C.S.; Lee, S.E.; Lu, S.Y.; McDermitt, D.J.; Osorio, K.M.; Piskun, C.M.; Peters, R.M.; Paus, R.; Timbar, T. Runx1 directly promotes proliferation of hair follicle stem cells and epithelial tumor formation in mouse skin. *Mol. Cell. Biol.* 2010, 30, 2518–2536. [CrossRef] [PubMed]

14. Martin, J.W.; Zielenska, M.; Stein, G.S.; van Wijnen, A.J.; Squire, J.A. The Role of RUNX2 in Osteosarcoma Oncogenesis. *Sarcoma* 2011, 2011, 282745. [CrossRef] [PubMed]

15. Onodera, Y.; Miki, Y.; Suzuki, T.; Takagi, K.; Akahira, J.; Sakya, T.; Watanabe, M.; Inoue, S.; Ishida, T.; Ohuchi, N.; et al. Runx2 in human breast carcinoma: Its potential roles in cancer progression. *Cancer Sci.* 2010, 101, 2670–2675. [CrossRef] [PubMed]
16. Keita, M.; Bachvarova, M.; Morin, C.; Plante, M.; Gregoire, J.; Renaud, M.C.; Sebastianelli, A.; Trinh, X.B.; Bachvarov, D. The RUNX1 transcription factor is expressed in serous epithelial ovarian carcinoma and contributes to cell proliferation, migration and invasion. Cell Cycle 2013, 12, 972–986. [CrossRef] [PubMed]

17. Taniuchi, I.; Osato, M.; Ito, Y. Runx1: No longer just for leukemia. EMBO J. 2012, 31, 4098–4099. [CrossRef]

18. Chen, F.; Liu, X.; Bai, J.; Fei, D.; Zheng, J. The emerging role of RUNX3 in cancer metastasis (Review). Oncol. Rep. 2016, 35, 1227–1236. [CrossRef]

19. Yi, H.; Li, G.; Long, Y.; Liang, W.; Cui, H.; Zhang, B.; Tan, Y.; Li, Y.; Shen, L.; Deng, D.; et al. Integrative multi-omics analysis of a colon cancer cell line with heterogeneous Wnt activity revealed RUNX2 as an epigenetic regulator of EMT. Oncogene 2020, 39, 5152–5164. [CrossRef]

20. van Bragt, M.P.; Hu, X.; Xie, Y.; Li, Z. RUNX1, a transcription factor mutated in breast cancer, controls the fate of ER-positive mammary luminal cells. elife 2014, 3, e03881. [CrossRef]

21. Chime, N.O.; Little, G.H.; Baniwal, S.K.; Adisetiyo, H.; Xie, Y.; Zhang, T.; O’Laughlin, A.; Liu, Z.Y.; Ulrich, P.; Martin, A.; et al. RUNX1 prevents oestrogen-mediated AXIN1 suppression and beta-catenin activation in ER-positive breast cancer. Nat. Commun. 2016, 7, 10751. [CrossRef] [PubMed]

22. Liu, C.; Xu, D.; Xue, B.; Liu, B.; Li, J.; Huang, J. Upregulation of RUNX1 Suppresses Proliferation and Migration through Repressing VEGFA Expression in Hepatocellular Carcinoma. Pathol. Oncol. Res. 2020, 26, 1301–1311. [CrossRef] [PubMed]

23. Li, Q.; Lai, Q.; He, C.; Fang, Y.; Yan, Q.; Zhang, Y.; Wang, X.; Gu, C.; Wang, Y.; Ye, L.; et al. RUNX1 promotes tumour metastasis by activating the Wnt/beta-catenin signalling pathway and EMT in colorectal cancer. J. Exp. Clin. Cancer Res. 2019, 38, 334. [CrossRef] [PubMed]

24. Lu, C.; Yang, Z.; Yu, D.; Lin, J.; Cai, W. RUNX1 regulates TGF-beta induced migration and EMT in colorectal cancer. Pathol. Res. Pract. 2020, 216, 153142. [CrossRef]

25. Niu, D.F.; Kondo, T.; Nakazawa, T.; Oishi, N.; Kawasaki, T.; Mochizuki, K.; Yamane, T.; Katoh, R. Transcription factor Runx2 is a regulator of epithelial-mesenchymal transition and invasion in thyroid carcinomas. Lab. Investig. 2012, 92, 1181–1190. [CrossRef]

26. Ozaki, T.; Yu, M.; Yin, D.; Sun, D.; Zhu, Y.; Bu, Y.; Sang, M. Impact of RUNX2 on drug-resistant human pancreatic cancer cells with p53 mutations. BMC Cancer 2018, 18, 309. [CrossRef]

27. Gao, J.; Chen, Y.; Wu, K.C.; Liu, J.; Zhao, Y.Q.; Pan, Y.L.; Du, R.; Zheng, G.R.; Xiong, Y.M.; Xu, H.L.; et al. RUNX3 directly interacts with intracellular domain of Notch1 and suppresses Notch signaling in hepatocellular carcinoma cells. Exp. Cell Res. 2010, 316, 149–157. [CrossRef]

28. Sun, G.; Zhang, C.; Feng, M.; Liu, W.; Xie, H.; Qin, Q.; Zhao, E.; Wan, L. Methylation analysis of p16, SLIT2, SCARA5, and Runx3 genes in hepatocellular carcinoma. Medicine 2017, 96, e8279. [CrossRef]

29. Lee, K.S.; Lee, Y.S.; Lee, J.M.; Ito, K.; Cinghiu, S.; Kim, J.H.; Jang, J.W.; Li, Y.H.; Goh, Y.M.; Chi, X.Z.; et al. RUNX3 is required for the differentiation of lung epithelial cells and suppression of lung cancer. Oncogene 2010, 29, 3349–3361. [CrossRef]

30. Lee, Y.S.; Lee, J.W.; Jang, J.W.; Chi, X.Z.; Kim, J.H.; Li, Y.H.; Kim, M.K.; Kim, D.M.; Choi, B.S.; Kim, E.G.; et al. RUNX3 inactivation is a crucial early event in the development of lung adenocarcinoma. Cancer Cell 2013, 24, 603–616. [CrossRef]

31. Herrero, A.M.; Ramirez, A.C.; Chaparro, V.P.; Fernandez, M.J.; Canas, A.; Morantes, C.F.; Moreno, O.M.; Bruges, R.E.; Mejia, J.A.; Bustos, F.J.; et al. Role of RUNX2 transcription factor in epithelial mesenchymal transition in non-small cell lung cancer lung cancer: Epigenetic control of the RUNX2 PI promoter. Tumour Biol. 2019, 41, 1010428319851014. [CrossRef] [PubMed]

32. Chen, K.; Liu, H.; Liu, Z.; Luo, S.; Patz, E.F., Jr.; Moorman, P.G.; Su, L.; Shen, S.; Christiani, D.C.; Wei, Q. Genetic variants in RUNX3, AMD1 and MSRA in the methionine metabolic pathway and survival in nonsmall cell lung cancer patients. Int. J. Cancer 2019, 145, 621–631. [CrossRef] [PubMed]

33. Lau, Q.C.; Raja, E.; Salto-Tellez, M.; Liu, Q.; Ito, K.; Inoue, M.; Putti, T.C.; Loh, M.; Ko, T.K.; Huang, C.; et al. RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. Cancer Res. 2006, 66, 6512–6520. [CrossRef]

34. Ferrari, N.; McDonald, L.; Morris, J.S.; Cameron, E.R.; Blyth, K. RUNX2 in mammary gland development and breast cancer. J. Cell. Physiol. 2013, 228, 1137–1142. [CrossRef]

35. Rossi, E.; Bagala, C.; Inzani, F.; Leoncini, E.; Brunelli, C.; Lanza, P.; Basso, M.; Mattucci, G.C.; Cassano, A.; Rindi, G.; et al. RUNX3 as a Potential Predictor of Metastasis in Human Pancreatic Cancer. In Vivo 2017, 31, 833–840. [CrossRef]

36. Kudo, Y.; Tsunematsu, T.; Takata, T. Oncogenic role of RUNX3 in head and neck cancer. J. Cell. Biochem. 2011, 112, 387–393. [CrossRef]

37. Sun, J.; Li, B.; Jia, Z.; Zhang, A.; Wang, G.; Chen, Z.; Shang, Z.; Zhang, C.; Cui, J.; Yang, W. RUNX3 inhibits glioma survival and invasion via suppression of the beta-catenin/TCF-4 signaling pathway. J. Neurooncol. 2018, 140, 15–26. [CrossRef]

38. Passaniti, A.; Brusgard, J.L.; Qiao, Y.; Sudol, M.; Finch-Edmondson, M. Roles of RUNX in Hippo Pathway Signaling. Adv. Exp. Med. Biol. 2017, 962, 435–448. [CrossRef]

39. Guo, Z.; Zhou, K.; Wang, Q.; Huang, Y.; Ji, J.; Peng, Y.; Zhang, X.; Zheng, T.; Zhang, Z.; Chong, D.; et al. The transcription factor RUNX2 fuels YAP1 signaling and gastric cancer tumorigenesis. Cancer Sci. 2021, 112, 3533–3544. [CrossRef]

40. Wang, L.; Li, D.; Liu, Y.; Wang, Y.; Cui, J.; Wu, W. Expression of RUNX3 and beta-catenin in the carcinogenesis of sporadic colorectal tubular adenoma. Tumour Biol. 2014, 35, 6039–6046. [CrossRef]

41. Sweeney, K.; Cameron, E.R.; Blyth, K. Complex Interplay between the RUNX Transcription Factors and Wnt/beta-Catenin Pathway in Cancer: A Tango in the Night. Mol. Cells 2020, 40, 188–197. [CrossRef] [PubMed]
42. Lebanon, D.; Groner, Y. Structure and regulated expression of mammalian RUNX genes. Oncogene 2004, 23, 4211–4219. [CrossRef] [PubMed]
43. Bae, S.C.; Kolinjivadi, A.M.; Ito, Y. Functional relationship between p53 and RUNX proteins. J. Mol. Cell. Biol. 2019, 11, 224–230. [CrossRef] [PubMed]
44. Samarakkody, A.S.; Shin, N.Y.; Cantor, A.B. Role of RUNX Family Transcription Factors in DNA Damage Response. Mol. Cells 2020, 43, 99–106. [CrossRef]
45. Marshall, I.J.; Moore, A.C.; Okhi, M.; Kitabayashi, I.; Patterson, D.; Ormelles, D.A. RUNX1 permits E4orf6-directed nuclear localization of the adenosine E1B-55K protein and associates with centers of viral DNA and RNA synthesis. J. Virol. 2008, 82, 6395–6408. [CrossRef]
46. Mevel, R.; Draper, J.E.; Lie, A.L.M.; Kouskoff, V.; Lacaud, G. RUNX transcription factors: Orchestrators of development. Development 2019, 146, dev148296. [CrossRef]
47. Sood, R.; Kamikubo, Y.; Liu, P. Role of RUNX1 in hematological malignancies. Blood 2017, 129, 2070–2082. [CrossRef]
48. Engel, M.E.; Hiebert, S.W. Proleukemic RUNX1 and CBFbeta mutations in the pathogenesis of acute leukemia. Cancer Treat. Res. 2010, 145, 127–147. [CrossRef]
49. Jagannathan-Bogdan, M.; Zon, L.I. Hematopoiesis. Development 2013, 140, 2463–2467. [CrossRef]
50. Gao, L.; Tober, J.; Gao, P.; Chen, C.; Tan, K.; Speck, N.A. RUNX1 and the endothelial origin of blood. Exp. Hematol. 2018, 68, 2–9. [CrossRef]
51. Ichikawa, M.; Yoshimi, A.; Nakagawa, M.; Nishimoto, N.; Watanabe-Okochi, N.; Kurokawa, M. A role for RUNX1 in hematopoiesis and myeloid leukemia. Int. J. Hematol. 2013, 97, 726–734. [CrossRef] [PubMed]
52. Li, S.; Kong, H.; Yao, N.; Yu, Q.; Wang, P.; Lin, Y.; Wang, J.; Kuang, R.; Zhao, X.; Xu, J.; et al. The role of runt-related transcription factor 2 (Runx2) in the late stage of odontoblast differentiation and dentin formation. Biochem. Biophys. Res. Commun. 2011, 410, 698–704. [CrossRef] [PubMed]
53. Komori, T. Runx2, an inducer of osteoblast and chondrocyte differentiation. Histochem. Cell. Biol. 2018, 149, 313–323. [CrossRef] [PubMed]
54. Dalle Carbonare, L.; Innamorati, G.; Valenti, M.T. Transcription factor Runx2 and its application to bone tissue engineering. Stem Cell. Res. Rep. 2012, 8, 891–897. [CrossRef]
55. Mundlos, S.; Otto, F.; Mundlos, C.; Mulliken, J.B.; Aylsworth, A.S.; Albright, S.; Lindhout, D.; Cole, W.G.; Henne, W.; Knoll, J.H.; et al. Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia. Cell 1997, 89, 773–779. [CrossRef]
56. Lee, B.; Thirunavukkarasu, K.; Zhou, L.; Pastore, L.; Baldini, A.; Hecht, J.; Geoffroy, V.; Ducy, P.; Karsenty, G. Missense mutations abolishing DNA binding of the osteoblast-specific transcription factor OSF2/CBFA1 in cleidocranial dysplasia. Nat. Genet. 1997, 16, 307–310. [CrossRef]
57. Lee, J.W.; van Wijnen, A.; Bae, S.C. RUNX3 and p53: How Two Tumor Suppressors Cooperate Against Oncogenic Ras? Adv. Exp. Med. Biol. 2017, 962, 321–332. [CrossRef]
58. Wang, J.W.; Stifani, S. Roles of Runx Genes in Nervous System Development. Adv. Exp. Med. Biol. 2017, 962, 103–116. [CrossRef]
59. Krishnan, V.; Ito, Y. A Regulatory Role for RUNX1 for RUNX3 in the Maintenance of Genomic Integrity. Adv. Exp. Med. Biol. 2017, 962, 491–510. [CrossRef]
60. Hyde, R.K.; Liu, P.; Friedman, A.D. RUNX1 and CBFbeta Mutations and Activities of Their Wild-Type Alleles in AML. Adv. Exp. Med. Biol. 2017, 962, 265–282. [CrossRef]
61. Lie, A.L.M.; Mevel, R.; Patel, R.; Blyth, K.; Baena, E.; Kouskoff, V.; Lacaud, G. RUNX1 Dosage in Development and Cancer. Mol. Cells 2020, 43, 126–138. [CrossRef]
62. Sangpairoj, K.; Viviathanaporn, P.; Apisawetakan, S.; Chongthammakun, S.; Sobhon, P.; Chaiathirayanon, K. RUNX1 Regulates Migration, Invasion, and Angiogenesis via p38 MAPK Pathway in Human Glioblastoma. Cell. Mol. Neurobiol. 2017, 37, 1243–1255. [CrossRef]
63. Liu, K.; Hu, H.; Jiang, H.; Zhang, H.; Gong, S.; Wei, D.; Yu, Z. RUNX1 promotes MAPK signaling to increase tumor progression and metastasis via OPN in head and neck cancer. Carcinogenesis 2021, 42, 414–422. [CrossRef] [PubMed]
64. Fritz, A.J.; Hong, D.; Boyd, J.; Kost, J.; Finstaad, K.H.; Fitzgerald, M.P.; Hanna, S.; Abuarqoub, A.H.; Malik, M.; Bushweller, J.; et al. RUNX1 and RUNX2 transcription factors function in opposing roles to regulate breast cancer stem cells. J. Cell. Physiol. 2020, 235, 7261–7272. [CrossRef] [PubMed]
65. Deltcheva, E.; Nimmo, R. RUNX transcription factors at the interface of stem cells and cancer. Biochem. J. 2017, 474, 1755–1768. [CrossRef] [PubMed]
66. Scheitz, C.J.; Lee, T.S.; McDermitt, D.J.; Tumbir, T. Defining a tissue stem cell-driven Runx1/Stat3 signalling axis in epithelial cancer. EMBO J. 2012, 31, 4124–4139. [CrossRef] [PubMed]
67. Ge, T.; Yin, M.; Yang, M.; Liu, T.; Lou, G. MicroRNA-302b suppresses human epithelial ovarian cancer cell growth by targeting RUNX1. Cell. Physiol. Biochem. 2014, 34, 2209–2220. [CrossRef]
68. Browne, G.; Taiapaleenmaki, H.; Bishop, N.M.; Madsu, S.C.; Shaw, L.M.; van Wijnen, A.J.; Stein, J.L.; Stein, G.S.; Lian, J.B. Runx1 is associated with breast cancer progression in MMTV-PyMT transgenic mice and its depletion in vitro inhibits migration and invasion. J. Cell. Physiol. 2015, 230, 2522–2532. [CrossRef]
Cells 2022, 11, 3687

69. Lau, C.C.; Harris, C.P.; Lu, X.Y.; Perlaky, L.; Gogineni, S.; Chintagumpala, M.; Hicks, J.; Johnson, M.E.; Davino, N.A.; Huvos, A.G.; et al. Frequent amplification and rearrangement of chromosomal bands 6p12-p21 and 17p11.2 in osteosarcoma. *Genes Chromosomes Cancer* 2004, 39, 11–21. [CrossRef]

70. Tandon, M.; Gokul, K.; Ali, S.A.; Chen, Z.; Lian, J.; Stein, G.S.; Pratap, J. Runx2 mediates epigenetic silencing of the bone morphogenetic protein-3B (BMP-3B/GDF10) in lung cancer cells. *Mol. Cancer* 2012, 11, 27. [CrossRef]

71. Chen, Y.; Wei, X.; Guo, C.; Jin, H.; Han, Z.; Han, Y.; Qiao, T.; Wu, K.; Fan, D. Runx3 suppresses gastric cancer metastasis through inactivation of MMP9 by upregulation of TIMP1. *Int. J. Cancer* 2011, 129, 1586–1598. [CrossRef] [PubMed]

72. Kim, B.R.; Park, S.H.; Jeong, Y.A.; Na, Y.J.; Kim, J.L.; Jo, M.J.; Jeong, S.; Yun, H.K.; Oh, S.C.; Lee, D.H. RUNX3 enhances TRAIL-induced apoptosis by upregulating DR5 in colorectal cancer. *Oncogene* 2019, 38, 3903–3918. [CrossRef] [PubMed]

73. Liu, H.; Yan, Z.; Yin, Q.; Cao, K.; Wei, Y.; Rodriguez-Canales, J.; Ma, D.; Wu, Y. RUNX3 Epigenetic Inactivation Is Associated With Estrogen Receptor Positive Breast Cancer. *J. Histochem. Cytochem.* 2018, 66, 709–721. [CrossRef] [PubMed]

74. Whittle, M.C.; Izeradjene, K.; Rani, P.G.; Feng, L.; Carlson, M.A.; DelGiorno, K.E.; Wood, L.D.; Goggins, M.; Hruban, R.H.; Chang, A.E.; et al. RUNX3 Controls a Metastatic Switch in Pancreatic Ductal Adenocarcinoma. *Cell* 2020, 182, 202. [CrossRef]

75. Cancer Genome Atlas, N. Comprehensive molecular portraits of human breast tumours. *Nature* 2012, 490, 61–70. [CrossRef]

76. Banerji, S.; Cibulskis, K.; Rangel-Escareno, C.; Brown, K.K.; Carter, S.L.; Frederick, A.M.; Lawrence, M.S.; Sivachenko, A.Y.; Sougnez, C.; Zou, L.; et al. Sequence analysis of mutations and translocations across breast cancer subtypes. *Nature* 2012, 486, 405–409. [CrossRef] [PubMed]

77. Ellis, M.J.; Ding, L.; Shen, D.; Luo, J.; Suman, V.J.; Wallis, J.W.; Van Tine, B.A.; Hoog, J.; Goiffon, R.J.; Goldstein, T.C.; et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. *Nature* 2012, 486, 353–360. [CrossRef] [PubMed]

78. Huang, J.; Hafberg Thulin, M.; Damber, J.E.; Welen, K. The roles of RUNX2 and osteoclasts in regulating expression of steroidogenic enzymes in castration-resistant prostate cancer cells. *Mol. Cell. Endocrinol.* 2021, 535, 111380. [CrossRef]

79. Sadikovic, B.; Thorner, P.; Chilton-Macneill, S.; Martin, J.W.; Cervigne, N.K.; Squire, J.; Zielienska, M. Expression analysis of genes associated with human osteosarcoma tumors shows correlation of RUNX2 overexpression with poor response to chemotherapy. *BMC Cancer* 2010, 10, 202. [CrossRef]

80. Kurek, K.C.; Del Mare, S.; Salah, Z.; Abdeen, S.; Sadiq, H.; Lee, S.H.; Gaudio, E.; Zanesi, N.; Jones, K.B.; DeYoung, B.; et al. Frequent attenuation of the WWOX tumor suppressor in osteosarcoma is associated with increased tumorigenicity and aberrant RUNX2 expression. *Cancer Res.* 2010, 70, 5577–5586. [CrossRef]

81. Vishal, M.; Swetha, R.; Thejaswini, G.; Arumugam, B.; Selvamurugan, N. Role of Runx2 in breast cancer-mediated bone metastasis. *Int. J. Biol. Macromol.* 2017, 99, 608–614. [CrossRef] [PubMed]

82. Ge, C.; Zhao, G.; Li, Y.; Li, H.; Zhao, X.; Pannone, G.; Bufo, P.; Santoro, A.; Sanguedolce, F.; Tortorella, S.; et al. Runx2 association with progression of prostate cancer in patients: Mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. *Oncogene* 2010, 29, 811–821. [CrossRef] [PubMed]

83. Peng, Z.; Wei, D.; Wang, L.; Tang, H.; Zhang, J.; Le, X.; Jia, Z.; Li, Q.; Xie, K. RUNX3 inhibits the expression of vascular endothelial growth factor and reduces the angiogenesis, growth, and metastasis of human gastric cancer. *Clin. Cancer Res.* 2006, 12, 6386–6394. [CrossRef]

84. Akech, J.; Wixted, J.J.; Bedard, K.; van der Deen, M.; Hussain, S.; Guise, T.A.; van Wijnen, A.J.; Stein, J.L.; Languino, L.R.; Altieri, D.C.; et al. Runx2 association with progression of prostate cancer in patients: Mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. *Oncogene* 2010, 29, 811–821. [CrossRef] [PubMed]

85. Ge, C.; Zhao, G.; Bufo, P.; Santoro, A.; Sanguedolce, F.; Tortorella, S.; et al. Role of Runx2 phosphorylation in prostate cancer and association with metastatic disease. *Oncogene* 2016, 35, 366–376. [CrossRef] [PubMed]

86. Akech, J.; Wixted, J.J.; Bedard, K.; van der Deen, M.; Hussain, S.; Guise, T.A.; van Wijnen, A.J.; Stein, J.L.; Languino, L.R.; Altieri, D.C.; et al. Runx2 association with progression of prostate cancer in patients: Mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. *Oncogene* 2010, 29, 811–821. [CrossRef] [PubMed]

87. Lim, M.; Zhong, C.; Yang, S.; Bell, A.M.; Cohen, M.B.; Roy-Burman, P. Runx2 regulates survivin expression in prostate cancer cells. *Lab. Invest.* 2010, 90, 222–233. [CrossRef]

88. Soong, R.; Shah, N.; Peh, B.K.; Chong, P.Y.; Ng, S.S.; Zeps, N.; Joseph, D.; Salto-Tellez, M.; Iacopetti, B.; Ito, Y. The expression of RUNX3 in colorectal cancer is associated with disease stage and patient outcome. *Br. J. Cancer* 2009, 100, 676–679. [CrossRef]

89. Richiard, L.; Fiano, V.; Vizzini, L.; De Marco, D.; Delsedime, L.; Akre, O.; Tos, A.G.; Merletti, F. Promoter methylation in APC, RUNX3, and GSTP1 and mortality in prostate cancer patients. *Clin. Cancer Res.* 2009, 15, 3161–3168. [CrossRef] [PubMed]

90. Xiao, Z.; Tian, Y.; Jia, Y.; Shen, Q.; Jiang, W.; Chen, G.; Shang, B.; Shi, M.; Wang, Z.; Zhao, X. RUNX3 inhibits the invasion and migration of esophageal squamous cell carcinoma by reversing the epithelialmesenchymal transition through TGFbeta/Smad signaling. *Oncol. Rep.* 2020, 43, 1289–1299. [CrossRef] [PubMed]

91. Subramaniam, M.M.; Chan, J.Y.; Soong, R.; Ito, K.; Ito, Y.; Yeoh, K.G.; Salto-Tellez, M.; Putti, T.C. RUNX3 inactivation by frequent promoter hypermethylation and protein mislocalization constitute an early event in breast cancer progression. *Breast Cancer Res. Treat.* 2009, 113, 113–121. [CrossRef]

92. Zheng, J.; Mei, Y.; Zhai, G.; Zhao, N.; Jia, D.; Fan, Y. Downregulation of RUNX3 has a poor prognosis and promotes tumor progression in kidney cancer. *Urol. Oncol.* 2020, 38, 740.e711–740.e720. [CrossRef]

93. Kim, B.R.; Na, Y.J.; Kim, J.L.; Jeong, Y.A.; Park, S.H.; Jo, M.J.; Jeong, S.; Kang, S.; Oh, S.C.; Lee, D.H. RUNX3 suppresses metastasis and stemness by inhibiting Hedgehog signaling in colorectal cancer. *Cell Death Differ.* 2020, 27, 676–694. [CrossRef] [PubMed]

94. Liu, H.; Yan, Z.; Yin, Q.; Cao, K.; Wei, Y.; Rodriguez-Canales, J.; Ma, D.; Wu, Y. RUNX3 Epigenetic Inactivation Is Associated With Estrogen Receptor Positive Breast Cancer. *J. Histochem. Cytochem.* 2018, 66, 709–721. [CrossRef] [PubMed]

95. Yu, F.; Gao, W.; Yokochi, T.; Suenaga, Y.; Ando, K.; Ohira, M.; Nakamura, Y.; Nakagawara, A. RUNX3 interacts with MYCN and facilitates protein degradation in neuroblastoma. *Oncogene* 2014, 33, 2601–2609. [CrossRef] [PubMed]
94. Hwang, K.T.; Han, W.; Bae, J.Y.; Hwang, S.E.; Shin, H.J.; Lee, J.E.; Kim, S.W.; Min, H.J.; Noh, D.Y. Downregulation of the RUNX3 gene by promoter hypermethylation and hemizygous deletion in breast cancer. J. Koran Med. Sci. 2007, 22, S24–S31. [CrossRef]

95. Jiang, Y.; Tong, D.; Lou, G.; Zhang, Y.; Geng. Expression of RUNX3 gene, methylation status and clinicopathological significance in breast cancer and breast cancer cell lines. Pathobiology 2008, 75, 244–251. [CrossRef] [PubMed]

96. Okuda, T.; Cai, Z.; Yang, S.; Lenny, N.; Lyu, C.J.; van Deursen, J.M.; Harada, H.; Downing, J.R. Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors. Blood 1999, 91, 3134–3143. [CrossRef]

97. Erickson, P.; Gao, J.; Chang, K.S.; Look, T.; Whisenant, E.; Raimondi, S.; Lasher, R.; Trujillo, J.; Rowley, J.; Drabkin, H. Identification of breakpoints in 1p(21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt. Blood 1992, 80, 1825–1831. [CrossRef]

98. Gao, J.; Aksoy, B.A.; Dogrusoz, U.; Dresdner, G.; Gross, B.; Sumer, S.O.; Sun, Y.; Jacobsen, A.; Sinha, R.; Larsson, E.; et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 2013, 6, p11. [CrossRef] [PubMed]

99. De Braekeleer, E.; Douet-Guilbert, N.; Morel, F.; Le Bris, M.J.; Ferec, C.; De Braekeleer, M. RUNX1 translocations and fusion genes in malignant hemopathies. Future Oncol. 2011, 7, 77–91. [CrossRef]

100. Medina, M.A.; Ugarte, G.D.; Vargas, M.F.; Avila, M.E.; Necunir, D.; Elorza, A.A.; Gutierrez, S.E.; De Ferrari, G.V. Alternative RUNX1 Promoter Regulation by Wnt/beta-Catenin Signaling in Leukemia Cells and Human Hematopoietic Progenitors. J. Cell. Physiol. 2016, 231, 1460–1467. [CrossRef]

101. Peng, Z.G.; Zhou, M.Y.; Huang, Y.; Qiu, J.H.; Wang, L.S.; Liao, S.H.; Dong, S.; Chen, G.Q. Physical and functional interaction of Runt-related protein 1 with hypoxia-inducible factor-1alpha. Oncogene 2008, 27, 839–847. [CrossRef] [PubMed]

102. Wu, H.; Zheng, J.; Deng, J.; Zhang, L.; Li, N.; Li, W.; Li, F.; Lu, J.; Zhou, Y. LncRNA-uc002yug2 involves in alternative splicing of RUNX1 and serves as a predictor for esophageal cancer and prognosis. Oncogene 2015, 34, 4723–4734. [CrossRef]

103. Wang, L.; Gural, A.; Sun, X.J.; Zhao, X.; Perna, F.; Huang, G.; Hatlen, M.A.; Vu, L.; Liu, F.; Xu, H.; et al. The leukemogenicity of AML1-ETO in vivo and alternative splicing of RUNX1. J. Biol. Chem. 2011, 286, 4528–4538. [CrossRef] [PubMed]

104. Sancisi, V.; Manzotti, G.; Gugnoni, M.; Rossi, T.; Gandolfi, G.; Gobbi, G.; Torricelli, F.; Catellani, F.; Faria do Valle, I.; Remondini, D.; et al. RUNX2 expression in thyroid and breast cancer requires the cooperation of three non-redundant enhancers under the control of BRD4 and c-JUN. Nucleic Acids Res. 2017, 45, 11294–11297. [CrossRef] [PubMed]

105. Gokulnath, M.; Partridge, N.C.; Selvanurugan, N. Runx2, a target gene for activating transcription factor-3 in human breast cancer cells. Tumor Biol. 2015, 36, 1923–1931. [CrossRef]

106. van der Deen, M.; Taipaleenmaki, H.; Zhang, Y.; Teplyuk, N.M.; Gupta, A.; Cinquela, S.; Shogren, K.; Maran, A.; Yaszemski, M.J.; van der Deen, M.; Taipaleenmaki, H.; Zhang, Y.; Teplyuk, N.M.; Gupta, A.; Cinquela, S.; Shogren, K.; Maran, A.; Yaszemski, M.J.; van Deursen, J.M.; Harada, H.; Downing, J.R. Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors. Blood 1999, 91, 3134–3143. [CrossRef]

107. Blyth, K.; Terry, A.; Mackay, N.; Vaillant, F.; Bell, M.; Cameron, E.R.; Neil, J.C.; Stewart, M. Runx2: A novel oncogenic effector transcription factor. Stem Cells 2006, 24, 2331–2342. [CrossRef] [PubMed]

108. Okuda, T.; Cai, Z.; Yang, S.; Lenny, N.; Lyu, C.J.; van Deursen, J.M.; Harada, H.; Downing, J.R. Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors. Blood 1999, 91, 3134–3143. [CrossRef]

109. Fu, Y.; Chang, A.C.; Fournier, M.; Chang, L.; Niessen, K.; Karsan, A. RUNX3 maintains the mesenchymal phenotype after termination of the Notch signal. J. Biol. Chem. 2011, 286, 11803–11813. [CrossRef]

110. Kim, H.R.; Oh, B.C.; Choi, J.K.; Bae, S.C. Pim-1 kinase phosphorylates and stabilizes RUNX3 and alters its subcellular localization. J. Cell. Biochem. 2008, 105, 1048–1058. [CrossRef]

111. Blyth, K.; Terry, A.; Mackay, N.; Vaillant, F.; Bell, M.; Cameron, E.R.; Neil, J.C.; Stewart, M. Runx2: A novel oncogenic effector revealed by in vivo complementation and retroviral tagging. Oncogene 2001, 20, 295–302. [CrossRef]

112. Yu, Y.; Chang, A.C.; Fournier, M.; Chang, L.; Niessen, K.; Karsan, A. RUNX3 maintains the mesenchymal phenotype after termination of the Notch signal. J. Biol. Chem. 2011, 286, 11803–11813. [CrossRef]

113. Kim, H.R.; Oh, B.C.; Choi, J.K.; Bae, S.C. Pim-1 kinase phosphorylates and stabilizes RUNX3 and alters its subcellular localization. J. Cell. Biochem. 2008, 105, 1048–1058. [CrossRef]

114. Meier-Stiegen, F.; Schwanbeck, R.; Bemmoth, K.; Martini, S.; Hieronymus, T.; Ruau, D.; Zenke, M.; Just, U. Activated Notch1 target genes during embryonic cell differentiation depend on the cellular context and include lineage determinants and inhibitors. PLoS ONE 2010, 5, e11481. [CrossRef] [PubMed]

115. Burns, C.E.; Traver, D.; Mayhall, E.; Shepard, J.L.; Zon, L.I. Hematopoietic stem cell fate is established by the Notch-Runx pathway. Genes Dev. 2005, 19, 2331–2342. [CrossRef] [PubMed]

116. Huang, J.; Zhao, L.; Xing, L.; Chen, D. MicroRNA-204 regulates Runx2 protein expression and mesenchymal progenitor cell differentiation. Stem Cells 2010, 28, 357–364. [CrossRef] [PubMed]

117. Zhang, Y.; Qian, W.; Feng, F.; Cao, Q.; Li, Y.; Hou, Y.; Zhang, L.; Fan, J. Upregulated IncRNA CASC2 May Inhibit Malignant Melanoma Development Through Regulating miR-18a-5p/RUNX1. Oncol. Res. 2019, 27, 371–377. [CrossRef] [PubMed]
Cells 2022, 11, 3687

119. Ji, Q.; Cai, G.; Liu, X.; Zhang, Y.; Wang, Y.; Zhou, L.; Sui, H.; Li, Q. MALAT1 regulates the transcriptional and translational levels of proto-oncogene RUNX2 in colorectal cancer metastasis. *Cell Death Dis.* 2019, 10, 378. [CrossRef]

120. D’Alonzo, R.C.; Selvamurugan, N.; Karsenty, G.; Partridge, N.C. Physical interaction of the activator protein-1 factors c-Fos and c-Jun with Cba1 for collagenase-3 promoter activation. *J. Biol. Chem.* 2002, 277, 816–822. [CrossRef]

121. Wildey, G.M.; Howe, P.H. Runx1 is a co-activator with FOXO3 to mediate transforming growth factor beta (TGFbeta)-induced cell cycle-dependent chromatin dynamics by functioning as a pioneer factor of the restriction-point.

122. Nam, S.; Jin, Y.H.; Li, Q.L.; Lee, K.Y.; Jeong, G.B.; Ito, Y.; Lee, J.; Baé, S.C. Expression pattern, regulation, and biological role of runt domain transcription factor, run, in *Caenorhabditis elegans*. *Mol. Cell. Biol.* 2002, 22, 547–554. [CrossRef] [PubMed]

123. Aho, T.L.; Sandholm, J.; Peltoha, K.J.; Ito, Y.; Koskinen, P.J. Pim-1 kinase phosphorylates RUNX family transcription factors and enhances their activity. *BMC Cell Biol.* 2006, 7, 21. [CrossRef]

124. Vermeulen, L.; De Sousa, E.M.F.; van der Heijden, M.; Cameron, K.; de Jong, J.H.; Borovski, T.; Tuyman, J.B.; Todaro, M.; Merz, C.; Rodermund, H.; et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. *Nat. Cell. Biol.* 2010, 12, 468–476. [CrossRef] [PubMed]

125. Zhan, T.; Rindtorff, N.; Boutros, M. Wnt signaling in cancer. *Oncogene* 2017, 36, 1461–1473. [CrossRef] [PubMed]

126. Mayall, T.P.; Sheridan, P.L.; Montminy, M.R.; Jones, K.A. Distinct roles for P-CREB and LEF-1 in TCR alpha enhancer assembly and activation on chromatin templates in vitro. *Genes Dev.* 1997, 11, 887–899. [CrossRef]

127. Ikushima, H.; Miyazono, K. TGFbeta signalling: A complex web in cancer progression. *Nat. Rev. Cancer* 2010, 10, 415–424. [CrossRef]

128. Zheng, K.; Yu, J.; Chen, Z.; Zhou, R.; Lin, C.; Zhang, Y.; Huang, Z.; Yu, L.; Zhao, L.; Wang, Q. Ethanol promotes alcohol-related colorectal cancer metastasis via the TGF-beta/RUNX3/Snail axis by inducing TGF-beta1 upregulation and RUNX3 cytoplasmic mislocalization. *EBioMedicine* 2019, 50, 224–237. [CrossRef]

129. Raghuwanshi, S.; Dahariya, S.; Sharma, D.S.; Kovuru, N.; Sahu, I.; Guitti, R.K. RUNX1 and TGF-beta signaling cross talk regulates Col2(+)-ion channels expression and activity during megakaryocyte development. *FEBS J.* 2020, 287, 5411–5438. [CrossRef]

130. Wildey, G.M.; Howe, P.H. Runx1 is a co-activator with FOX03 to mediate transforming growth factor beta (TGFbeta)-induced Bim transcription in hepatic cells. *J. Biol. Chem.* 2009, 284, 20227–20239. [CrossRef]

131. Jang, J.W.; Kim, M.K.; Lee, Y.S.; Lee, J.W.; Kim, D.M.; Song, S.H.; Lee, J.Y.; Choi, B.Y.; Min, B.; Chi, X.Z.; et al. RAC-LATS1/2 signaling regulates YAP activity by switching between the YAP-binding partners TEAD4 and RUNX3. *Oncogene* 2017, 36, 999–1011. [CrossRef] [PubMed]

132. Liu-Chittenden, Y.; Huang, B.; Shim, J.S.; Chen, Q.; Lee, S.J.; Anders, R.A.; Liu, J.O.; Pan, D. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. *Genes Dev.* 2012, 26, 1300–1305. [CrossRef] [PubMed]

133. Qiao, Y.; Lin, S.J.; Chen, Y.; Voon, D.C.; Zhu, F.; Chuang, L.S.; Wang, T.; Tan, P.; Lee, S.C.; Yeoh, K.G.; et al. RUNX3 is a novel negative regulator of oncogenic TEAD-YAP complex in gastric cancer. *Oncogene* 2016, 35, 2664–2674. [CrossRef] [PubMed]

134. Brusgard, J.L.; Choe, M.; Chumski, S.; Renoud, K.; MacKerell, A.D.; Jr.; Sudol, M.; Passaniti, A. RUNX2 and TAZ-dependent signaling pathways regulate soluble E-Cadherin levels and tumorsphere formation in breast cancer cells. *Oncotarget* 2015, 6, 28132–28150. [CrossRef] [PubMed]

135. Lin, F.C.; Liu, Y.P.; Lai, C.H.; Shan, Y.S.; Cheng, H.C.; Hsu, P.L.; Lee, C.H.; Lee, Y.C.; Wang, H.Y.; Wang, C.H.; et al. RUNX3-mediated transcriptional inhibition of Akt suppresses tumorigenesis of human gastric cancer cells. *Oncogene* 2012, 31, 4302–4316. [CrossRef] [PubMed]

136. Ito, K. RUNX3 in oncogenic and anti-oncogenic signaling in gastrointestinal cancers. *J. Cell. Biochem.* 2011, 112, 1243–1249. [CrossRef] [PubMed]

137. Magnani, L.; Eeckhoute, J.; Lupien, M. Pioneer factors: Directing transcriptional regulators within the chromatin environment. *Trends Genet.* 2011, 27, 465–474. [CrossRef] [PubMed]

138. Lee, J.W.; Kim, D.M.; Jang, J.W.; Park, T.G.; Song, S.H.; Lee, Y.S.; Chi, X.Z.; Park, I.Y.; Hyun, J.W.; Ito, Y.; et al. RUNX3 regulates cell cycle-dependent chromatin dynamics by acting as a pioneer factor of the restriction-point. *Nat. Commun.* 2019, 10, 1897. [CrossRef]

139. Subramaniam, M.M.; Chan, J.Y.; Soong, R.; Ito, K.; Yeoh, K.G.; Wong, R.; Guenther, T.; Will, O.; Chen, C.L.; Kumarasinghe, M.P.; et al. RUNX3 inactivation in colorectal polyps arising through different pathways of colonic carcinogenesis. *Am. J. Gastroenterol.* 2009, 104, 426–436. [CrossRef]

140. Lee, J.H.; Pyon, J.K.; Kim, D.W.; Lee, S.H.; Nam, H.S.; Kang, S.G.; Kim, C.H.; Lee, Y.J.; Chun, J.S.; Cho, M.K. Expression of RUNX3 in skin cancers. *Clin. Exp. Dermatol.* 2011, 36, 769–774. [CrossRef]

141. Cheng, H.C.; Liu, Y.P.; Shao, Y.S.; Huang, C.Y.; Lin, F.C.; Lin, L.C.; Lee, L.; Tsai, C.H.; Hsiao, M.; Lu, P.J. Loss of RUNX3 increases osteopontin expression and promotes cell migration in gastric cancer. *Carcinogenesis* 2013, 34, 2452–2459. [CrossRef] [PubMed]

142. Yu, G.P.; Ji, Y.; Chen, G.Q.; Huang, B.; Shen, K.; Wu, S.; Shen, Z.Y. Application of RUNX3 gene promoter methylation in the diagnosis of non-small cell lung cancer. *Oncol. Lett.* 2012, 3, 159–162. [CrossRef] [PubMed]